Cassava Sciences, Inc. (NASDAQ:SAVA - Get Free Report) insider James William Kupiec sold 4,000 shares of the firm's stock in a transaction on Friday, November 29th. The shares were sold at an average price of $3.87, for a total value of $15,480.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Cassava Sciences Trading Down 2.6 %
NASDAQ:SAVA opened at $3.35 on Wednesday. The stock has a market capitalization of $161.17 million, a P/E ratio of -2.43 and a beta of -0.86. Cassava Sciences, Inc. has a 1 year low of $3.25 and a 1 year high of $42.20. The firm has a 50 day moving average of $23.95 and a 200-day moving average of $22.52.
Cassava Sciences (NASDAQ:SAVA - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.58) EPS for the quarter, topping analysts' consensus estimates of ($1.37) by $0.79. During the same quarter in the prior year, the business posted ($0.61) EPS. As a group, analysts forecast that Cassava Sciences, Inc. will post -3.97 EPS for the current fiscal year.
Analysts Set New Price Targets
Video: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You
From Brownstone Research | Ad
“Hi, I’m Jeff Brown…
Even though I can’t see a thing…
I’m about to get in this Cybertruck and drive up to a location just a few miles from here to show you Elon Musk’s next AI product.
I promise what happens next will shock you…”
Click here to see what happened
Several research firms have weighed in on SAVA. HC Wainwright cut shares of Cassava Sciences from a "buy" rating to a "neutral" rating and set a $116.00 price objective on the stock. in a research report on Tuesday, November 26th. Rodman & Renshaw reaffirmed a "buy" rating and set a $107.00 target price on shares of Cassava Sciences in a research report on Thursday, August 8th.
Get Our Latest Stock Report on SAVA
Institutional Trading of Cassava Sciences
Institutional investors have recently bought and sold shares of the business. International Assets Investment Management LLC acquired a new position in shares of Cassava Sciences in the 3rd quarter valued at approximately $10,610,000. KBC Group NV acquired a new position in shares of Cassava Sciences in the third quarter valued at approximately $57,000. CANADA LIFE ASSURANCE Co increased its position in shares of Cassava Sciences by 146.7% during the first quarter. CANADA LIFE ASSURANCE Co now owns 9,408 shares of the company's stock worth $191,000 after acquiring an additional 5,594 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Cassava Sciences by 1.4% during the first quarter. Vanguard Group Inc. now owns 2,356,480 shares of the company's stock worth $47,813,000 after acquiring an additional 31,854 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in shares of Cassava Sciences by 18.1% during the second quarter. Bank of New York Mellon Corp now owns 140,847 shares of the company's stock worth $1,739,000 after acquiring an additional 21,558 shares during the period. Institutional investors and hedge funds own 38.05% of the company's stock.
Cassava Sciences Company Profile
(
Get Free Report)
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
